ClinicalTrials.gg
CompletedNCT05996848REDEFINE 6Updated Jan 9, 2026

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

A Phase 3 interventional study of Cagrilintide and Semaglutide in Obesity or Overweight, sponsored by Novo Nordisk A/S. Completed at 37 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cagrilintide in Obesity — 9 open to participants now, 15 under way, 9 of them phase 3. cagrilintide · Obesity.

Enrollment
13th of 36
300 · median 154
Started
2023
with 4 others
Phase 3
15 of 36
4 open now
Registered
13th of 36
by date
Lead sponsor
36 of 36
Novo Nordisk A/S

Among the 36 studies testing cagrilintide in Obesity, this one is the 13th largest by enrollment, is one of 5 that started in 2023, is one of 15 in phase 3, and was the 13th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

9 of the 36 studies testing cagrilintide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cagrilintide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cagrilintide in Obesity, or all of them as a file.
02

Study summary

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.

03

Conditions studied

  • Obesity or Overweight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age above or equal to 18 years at the time of signing

    1. (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or
    2. BMI greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to, type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

For participants with Type 2 diabetes (T2D) at screening the following criteria also apply:

  • Diagnosed with type 2 diabetes mellitus greater than equal to 180 days before screening
  • Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i)), thiazolidinediones, or sulphonylureas (SUs) as a single agent or in combination) according to local label
  • Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) for at least 60 days before screening
  • (HbA1c) 7 percent-10 percent (53-86 millimoles per mole [mmol/mol]) (both inclusive) as measured by the central laboratory at screening

Exclusion criteria

Exclusion Criteria:

For participants without T2D at screening:

  • greater than or equal to 6.5 percent (48 mmol/mol) as measured by the central laboratory at screening
  • History of type 1 or type 2 diabetes mellitus

For participants with T2D at screening:

  • or severe hypoglycaemia within 6 months before screening or history of hypoglycaemia unawareness
  • Renal impairment with estimated (eGFR) lesser than 30 milli liter per min/1.73 meter square (mL/min/1.73 m\^2), as measured by the central laboratory at screening
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    CagriSema

    Participants will receive once-weekly subcutaneous (s.c) injections of 2.4 mg cagrilintide and 2.4 mg semaglutide for 44 weeks.

    Drug: Cagrilintide · Drug: Semaglutide

  • Active comparator
    Semaglutide

    Participants will receive once-weekly s.c injection of 2.4 mg semaglutide for 44 weeks.

    Drug: Semaglutide · Drug: Placebo Semaglutide

  • Placebo comparator
    Placebo

    Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide once weekly for 44 weeks.

    Drug: Placebo Semaglutide · Drug: Placebo Cagrilintide

Interventions

  • Participants will receive 2.4 mg cagrilintide subcutaneously.

  • Participants will receive 2.4 mg semaglutide subcutaneously.

  • DrugPlacebo Semaglutide

    Participants will receive placebo matched to semaglutide subcutaneously.

  • DrugPlacebo Cagrilintide

    Participants will receive placebo matched to cagrilintide subcutaneously.

06

What researchers measure

Primary outcomes

  1. CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  2. CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 5%

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 44)

Secondary outcomes

  1. CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 20%

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 44)

  2. CagriSema 2.4 mg/2.4 mg versus semaglutide 2.4 mg: Relative change in body weight

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  3. CagriSema 2.4 mg/2.4 mg versus placebo: Change in waist circumference

    Measured in centimeter (cm)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  4. CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 10%

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 44)

  5. CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 15%

    Measured as count of participants

    Time frame: From baseline (week 0) to end of treatment (week 44)

  6. CagriSema 2.4 mg/2.4 mg versus semaglutide 2.4 mg: Change in waist circumference

    Measured in centimeter (cm)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  7. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Change in Glycated Haemoglobin (HbA1c)

    Measured in percentage points

    Time frame: From baseline (week 0) to end of treatment (week 44)

  8. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Change in Fasting Plasma Glucose (FPG)

    Measured as millimole per liter (mmol/L)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  9. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in fasting serum insulin

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  10. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Change in Systolic Blood Pressure (SBP)

    Measured in millimeter of mercury (mmHg)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  11. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Change in Diastolic Blood Pressure (DBP)

    Measured in millimeter of mercury (mmHg)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  12. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in total cholesterol

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  13. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in high-density lipoprotein (HDL) cholesterol

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  14. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in low-density lipoprotein (LDL) cholesterol

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  15. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in very low-density lipoprotein (VLDL) cholesterol

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  16. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in triglycerides

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  17. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Relative change in free fatty acids

    Measured in percentage (%)

    Time frame: From baseline (week 0) to end of treatment (week 44)

  18. CagriSema 2.4 mg/2.4 mg versus placebo: Change in Short Form-36 Version 2.0 (SF- 36v2) Physical Functioning score

    Measured as score points. The SF-36v2.0 is a 36-item commonly used generic clinical outcome assessment (COA) instrument measuring health-related quality of life and general health status across disease areas. SF-36v2 questionnaire measures 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This endpoint assess the 'physical functioning domain'. The 0-100 scale scores from the SF-36 will be converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 correspond to the mean and standard deviation respectively. A positive change score indicates an improvement since baseline.

    Time frame: From baseline (week 0) to end of treatment (week 44)

  19. CagriSema 2.4 mg/2.4 mg versus placebo: Change in SF-36v2: Physical Component Summary Score

    Measured as score points. The SF-36v2.0 is a 36-item commonly used generic COA instrument measuring health-related quality of life and general health status across disease areas. SF-36v2 questionnaire measures 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This endpoint assess the 'physical component summary'. The 0-100 scale scores from the SF-36 will be converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively. A positive change score indicates an improvement since baseline.

    Time frame: From baseline (week 0) to end of treatment (week 44)

  20. CagriSema 2.4 mg/2.4 mg versus placebo: Change in SF-36v2: Mental Component Summary score

    Measured as score points. The SF-36v2.0 is a 36-item commonly used generic COA instrument measuring health-related quality of life and general health status across disease areas. SF-36v2 questionnaire measures 8 domains of functional health and well-being as well as 2 component summary scores (physical component summary and mental component summary). This endpoint assess the 'mental component summary'. The 0-100 scale scores from the SF-36 will be converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively. A positive change score indicates an improvement since baseline.

    Time frame: From baseline (week 0) to end of treatment (week 44)

  21. CagriSema 2.4 mg/2.4 mg versus placebo: Change in Impact of Weight on Quality Of Life-Lite Clinical Trials Version (IWQOLLite- CT) Physical Function score

    Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patient's physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. This endpoint assess the 'physical function score'. The scores range between 0-100 where higher scores indicate a better quality of life. A positive change score indicates an improvement since baseline.

    Time frame: From baseline (week 0) to end of treatment (week 44)

  22. CagriSema 2.4 mg/2.4 mg versus placebo: Change in IWQOL-Lite-CT Total score

    Measured as score points. IWQOL-Lite-CT version 3 is a 20-item COA instrument used to assess the impact of body weight changes in obesity studies on patient's physical and psychosocial functioning in three composite scores (physical function, physical and psychosocial) and a total score. This endpoint assess the 'total score'. The scores range between 0-100 where higher scores indicate a better quality of life. A positive change score indicates an improvement since baseline.

    Time frame: From baseline (week 0) to end of treatment (week 44)

  23. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Number of Treatment Emergent Adverse Events (TEAEs)

    Measured as count of events

    Time frame: From baseline (week 0) to end of study (week 51)

  24. CagriSema 2.4 mg/2.4 mg versus placebo and semaglutide 2.4 mg: Number of Treatment Emergent Serious Adverse Events (TESAEs)

    Measured as count of events

    Time frame: From baseline (week 0) to end of study (week 51)

  25. Number of clinically significant hypoglycaemic episodes (level 2) (lesser than 3.0 mmol/L (54 milligrams per deciliter[mg/dL]), confirmed by BG meter) (only for participants with Type 2 diabetes (T2D) at screening)

    Measured as count of episodes

    Time frame: From baseline (week 0) to end of study (week 51)

  26. Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold (only for participants with T2D at screening)

    Measured as count of episodes

    Time frame: From baseline (week 0) to end of study (week 51)

07

Study locations

37 sites
  • Chinese People's Liberation Army General Hospital-Endocrinology
    Beijing, Beijing Municipality 100853, China
  • Chongqing University Three Gorges Hospital
    Chongqing, Chongqing Municipality 404000, China
  • Fujian Medical University Union Hospital-Endocrinology
    Fuzhou, Fujian 350001, China
  • Huizhou Central People's Hospital-Endocrinology
    Huizhou, Guangdong 516001, China
  • Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology
    Hengshui, Hebei 053000, China
  • The Second Hospital of Hebei Medical University-Endocrinology
    Shijiazhuang, Hebei 050000, China
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Huaihe Hospital of Henan University-Endocrinology
    Kaifeng, Henan 475000, China
  • Huaihe Hospital of Henan University
    Kaifeng, Henan 475000, China
  • The First Affiliated Hospital of Henan University of Science and Technology-Endocrinology
    Luoyang, Henan 471003, China
  • The First Affiliated Hospital of Henan university of Science
    Luoyang, Henan 471003, China
  • The Second Affiliated Hospital of Zhengzhou University-Endocrinology
    Zhengzhou, Henan 450003, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450003, China
  • The First People's Hospital of Changde City-Endocrinology
    Changde, Hunan 415003, China
  • Changzhou No.2 People's Hospital
    Changzhou, Jiangsu 213003, China
  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 213003, China
  • The First People's Hospital of Changzhou
    Changzhou, Jiangsu 213004, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Suzhou Municipal Hospital-Endocrinology
    Suzhou, Jiangsu 215002, China
  • The First Affiliated Hospital of Soochow University-Endocrinology
    Suzhou, Jiangsu 215006, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu 221002, China
  • The Affiliated Hospital of Jiangsu University
    Zhenjiang, Jiangsu 212001, China
  • The first hospital of Jilin University
    Changchun, Jilin 130021, China
  • The First Bethune hospital of Jilin University-Endocrinology
    Changchun, Jilin 130061, China
  • Jinan Central Hospital
    Ji'nan, Shandong 250013, China
  • Jinan Central Hospital
    Jin'an, Shandong 250013, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Huashan Hospital Fudan University
    Shanghai, Shanghai Municipality 200040, China
  • Tongren Hospital Shanghai Jiao Tong Univ. School of Medicine
    Shanghai, Shanghai Municipality 200336, China
  • Tongren Hospital Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200336, China
  • Central Hospital of Minhang District, Shanghai-Endocrinology
    Shanghai, Shanghai Municipality 201199, China
  • Central Hospital of Minhang District-Endocrinology
    Shanghai, Shanghai Municipality 201199, China
  • Shanghai Pudong New Area People's Hospital-Endocrinology
    Shanghai, Shanghai Municipality 201200, China
  • General Hospital of Tianjin Medical University-Endocrinology
    Tianjin, Tianjin Municipality 300052, China
  • General Hospital of Tianjin Medical University
    Tianjin, Tianjin Municipality 300052, China
  • The Second Hospital of Tianjin Medical University
    Tianjin, Tianjin Municipality 300211, China
  • Huashan Hospital Fudan University
    Jingan/Shanghai, 200040, China
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Jan 2025, 16 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 16 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2023
First posted
Aug 18, 2023
StartActual
Aug 15, 2023
Primary completionActual
Jan 6, 2025
CompletionActual
Feb 22, 2025
Results delay requested
Jan 4, 2026
Last update
Jan 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05996848
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Aug 18, 2023
Start date
Aug 15, 2023
Primary completion
Jan 6, 2025
Completion
Feb 22, 2025
Last update
Jan 9, 2026

Study contacts

Clinical Reporting Office (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cagrilintide

Start the discussion